Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Sullivan

Showing results (1-10 of 326) with videos related to

Pageof 33
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2023
To Inhibit or Not to Inhibit MEK With BRAF Inhibitors: Is That the Question?Ryan J Sullivan
Cancer Discovery|April 1, 2022
For Whom the Bell Tolls? A Toll-Like Receptor 9 Agonist's Journey from Vaccine Adjuvant to Promising Agent in Anti-PD-1-Resistant MelanomaRyan J Sullivan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2018
Forestalling BRAF-Inhibitor Resistance in a Shocking WayRyan J Sullivan
Current Opinion in Oncology|February 5, 2016
The role of mitogen-activated protein targeting in melanoma beyond BRAFV600Ryan J Sullivan
Future Oncology (London, England)|August 23, 2017
The evolutionary nature of the cancer immunotherapy revolutionRyan J Sullivan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2022
What, if Any, Role Is There for BRAF-Targeted Therapy in <i>BRAF</i>-Mutant Melanoma?Ryan J Sullivan
Clinical Advances in Hematology & Oncology : H&O|June 22, 2022
The role of triple therapy in BRAF-positive melanomaRyan J Sullivan
Cancer Discovery|May 3, 2018
Dual MAPK/CDK Targeting in Melanoma: New Approaches, New ChallengesRyan J Sullivan
Seminars in Cutaneous Medicine and Surgery|July 25, 2018
The role of targeted therapy for melanoma in the immunotherapy eraRyan J Sullivan
Cancer Discovery|June 5, 2019
Back to the Future: Rethinking and Retooling IL2 in the Immune Checkpoint Inhibitor EraRyan J Sullivan
Pageof 33

Showing results (1-10 of 326) with videos related to

Sort By:
Pageof 33
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2023
To Inhibit or Not to Inhibit MEK With BRAF Inhibitors: Is That the Question?Ryan J Sullivan
Cancer Discovery|April 1, 2022
For Whom the Bell Tolls? A Toll-Like Receptor 9 Agonist's Journey from Vaccine Adjuvant to Promising Agent in Anti-PD-1-Resistant MelanomaRyan J Sullivan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2018
Forestalling BRAF-Inhibitor Resistance in a Shocking WayRyan J Sullivan
Current Opinion in Oncology|February 5, 2016
The role of mitogen-activated protein targeting in melanoma beyond BRAFV600Ryan J Sullivan
Future Oncology (London, England)|August 23, 2017
The evolutionary nature of the cancer immunotherapy revolutionRyan J Sullivan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2022
What, if Any, Role Is There for BRAF-Targeted Therapy in <i>BRAF</i>-Mutant Melanoma?Ryan J Sullivan
Clinical Advances in Hematology & Oncology : H&O|June 22, 2022
The role of triple therapy in BRAF-positive melanomaRyan J Sullivan
Cancer Discovery|May 3, 2018
Dual MAPK/CDK Targeting in Melanoma: New Approaches, New ChallengesRyan J Sullivan
Seminars in Cutaneous Medicine and Surgery|July 25, 2018
The role of targeted therapy for melanoma in the immunotherapy eraRyan J Sullivan
Cancer Discovery|June 5, 2019
Back to the Future: Rethinking and Retooling IL2 in the Immune Checkpoint Inhibitor EraRyan J Sullivan
Pageof 33